Home infusion company’s experience with pediatric outpatient milrinone therapy

0

Milrinone is a phosphodiesterase 3 inhibitor with both positive inotropic and vasodilator properties. Administered as a continuous infusion, milrinone is indicated for the short-term treatment of patients with acute decompensated heart failure” Curley et al (2017).

Abstract:

Milrinone is a phosphodiesterase 3 inhibitor with both positive inotropic and vasodilator properties. Administered as a continuous infusion, milrinone is indicated for the short-term treatment of patients with acute decompensated heart failure. Despite limited data supporting long-term milrinone therapy in adults with congestive heart failure, children managed as outpatients may benefit from continuous milrinone as a treatment for cardiac dysfunction, as a destination therapy for cardiac transplant, or as palliative therapy for cardiomyopathy. The aim of this article is to review the medical literature and describe a home infusion company’s experience with pediatric outpatient milrinone therapy.

Full Text

Reference:

Curley, M., Liebers, J. and Maynard, R. (2017) Continuous Intravenous Milrinone Therapy in Pediatric Outpatients. Journal of Infusion Nursing. 40(2), p.92–96.

doi: 10.1097/NAN.0000000000000214

Thank you to our partners for supporting IVTEAM

Share.

Comments are closed.